Neoadjuvant treatment versus upfront surgery in borderline resectable and resectable pancreatic ductal adenocarcinoma: meta-analysis
➡️https://t.co/NvpYCbVYcJ
This comprehensive systematic review and meta-analysis of nine trials and 1194 patients comparing neoadjuvant treatments to upfront surgery demonstrates improved overall survival in neoadjuvant treatment arms. This benefit is pronounced in borderline-resectable patients but there is no difference between chemotherapy and chemoradiotherapy. R0 and N0 rates are improved whilst surgical complications and significant adverse effects are comparable.
👏👏👏@MrLDDickerson, @JaydenGittens, Chris Brunning, Richard Jackson, Michael C Schmid, Ainhoa Mielgo, Daniel Palmer, Christopher M Halloran, Paula Ghaneh
#SoMe4Surgery #MedTwitter #SurgEd #Surgery @BJSAcademy@BJSurgery@young_bjs@juliomayol@JJEarnshaw @OUPMedicine #some4hpb #some4tpl #PancreaticCancer #PancreaticSurgery @YouppiePancreas@German_PancClub@surgery_hps #PancreasClub2023 @PancreasClub@DPCG_official@pancreatitis_nl@PanCAN #PanCANawareness @EurPancClub@P_C_E_@dice_europe
@DrDMcGregor Strong disagree on this - refusing doesn’t mean strike. It means further discussion on the points of contention. There needs to be a contractual commitment to FPR. Worked for a consultant whose pet phrase was “trust no-one, believe nothing”. Politicians need to be treated as such
It’s not pay restoration and there is no commitment to it. Worse than offers given to Scottish doctors. Just because Labour in charge we shouldn’t take their first offer.. there needs to be written commitment to restoration (over number of years). Vote against.
Junior doctors in England 📢📢📢
Your dedication to pay restoration has paid off. We have successfully negotiated an offer with the Government that we believe is credible enough for you to have your say.
Visit the link below for more information:
https://t.co/W4wO1ko7QP
@TheDA_UK@NuffieldTrust This is a terrible survey - regardless of the results it can be spun to fit a pre-ordained narrative. Nothing meaningful can come from completing this. Additional number will simply add ‘strength’ to the spurious ‘results’.
@DoctorMayJay Risk tolerance. So I asked this before my laser eye surgery and the ophthalmologist said it was because they needed binocular vision for the microscope work and couldn’t risk minor discrepancies between eyes. It’s by far the best thing I’ve done.
BMA junior doctor members in England have voted by over 97% in favour of extending our mandate for industrial action, and to provide us with a mandate for action short of strike (ASOS).
A huge thank you to all of those who voted.
Read the full results 👇
https://t.co/IQb1unyESf
Really pleased to see that MPs have been awarded a 5.5% pay rise. How lucky they are. Makes it 38% since 2010. Would say that it’s not unreasonable for junior doctors to have similar? #payrestoration @BMA_JuniorDocs
https://t.co/WqZbrrGjXF
@sleepy__doc I agree it shouldn’t be the main role of F1 but it’s an important part of knowing and managing the patients.. I actually think that F1s need more ownership of the patients they manage. Presenting them every morning etc.
@MStott88 I don’t really follow what you’re saying.. current available data is the size of tumour (granted this has limitations) but survival curves separate at these values therefore these are the subgroups. TNM isn’t about comparing between cancers it’s about prognosticating that cancer.
@MStott88 What do you mean by artificially decided TNM? These pathological variables have been statistically modelled through various iterations to correlate with survival and then been validated through subgroup analysis of RCTs.
💫DON’T MISS @NatureCancer “Efferocytosis reprograms the tumor microenvironment to promote pancreatic cancer liver metastasis” #metastasis
https://t.co/C0z0Eq2i9L
Incredibly impressive work in collaboration and recruiting all these patient. But equally incredibly disappointing 61% still receive no treatment. Active engagement will eventually change face to PDAC but it’s going to take time and similar efforts internationally
Can one randomize all patients with #PancreaticCancer in a single country 🇳🇱 in a stepped-wedge RCT to improve guideline-based care? Yes✅ #PACAP1
Did this improve treatment nationwide? Yes, partially✅
Did this improve survival? No⛔️
🔑 Why? 61% of 5800+ patients received no cancer-directed treatment… @DPCG_official
Today: #PACAP1 trial in @JAMASurgery https://t.co/C6CrxqQ5yo
@MStott88 @jaldmn @briwbri Couldn’t agree more - it’s to allow us to convey the risk to the patient and relatives and signpost appropriate post op care (CritCare, Geris etc).. using it to choose what care it backwards as we should have decided that already based on clinical!
@MStott88 @ASiTofficial Couldn’t agree more on this - the SHOs get dissuaded from surgery (if they aren’t already by the myriad of other factors) and before we know I there’s no-one behind us. Who are our colleagues of the future? How well trained will they be if they aren’t getting trained